



Photos and Captions – October 24, 2017



Noramco introduces controlled substance development solutions at CPhI Worldwide

The company is integrating its API development offering to include all of the technologies and services generic and branded pharmaceutical producers require to advance solutions to market.



Noramco and SPI Pharma sign letter of intent to develop formulation solution packages

Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services, signed a letter of intent to develop and license formulation packages, specifically for implementation by their customers.



Noramco introduces a turnkey approach to cannabinoid APIs at CPhI Worldwide

Noramco is moving forward with a broad offering of clinical to commercial scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.